Potent and selective NOP receptor activation reduces cocaine self-administration in rats by lowering hedonic set point.
Autor: | Cippitelli A; Biomedical Science Department, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, United States., Barnes M; Biomedical Science Department, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, United States., Zaveri NT; Astraea Therapeutics Inc., Mountain View, CA, United States., Toll L; Biomedical Science Department, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, United States. |
---|---|
Jazyk: | angličtina |
Zdroj: | Addiction biology [Addict Biol] 2020 Nov; Vol. 25 (6), pp. e12844. Date of Electronic Publication: 2019 Nov 10. |
DOI: | 10.1111/adb.12844 |
Abstrakt: | Developing new medications for the treatment of cocaine dependence continues to be a research priority. Compelling evidence indicates that mixed opioid receptor agonists, particularly bifunctional compounds that target nociceptin/orphanin FQ peptide (NOP) and mu opioid receptors, may be useful for the treatment of cocaine addiction. Here, we verify that potent and selective pharmacological activation of NOP receptors is sufficient to reduce relevant facets of cocaine addiction in animal models. Accordingly, we determined whether systemic injections of the small molecule AT-312 (0, 1, 3 mg/kg) could reduce operant cocaine self-administration, motivation for cocaine, and vulnerability to cocaine relapse in rats. Results indicate that a potent and selective NOP receptor agonist was equally efficacious in reducing the number of cocaine infusions in short (1-hour), as well as long (6-hour) access sessions. When tested on an economic-demand reinforcement schedule, AT-312 reduced Q (© 2019 Society for the Study of Addiction.) |
Databáze: | MEDLINE |
Externí odkaz: |